Jafron BiomedicalLtd Future Growth
Future criteria checks 6/6
Jafron BiomedicalLtd is forecast to grow earnings and revenue by 26.9% and 24.6% per annum respectively. EPS is expected to grow by 26.5% per annum. Return on equity is forecast to be 26.4% in 3 years.
Key information
26.9%
Earnings growth rate
26.5%
EPS growth rate
| Medical Equipment earnings growth | 23.9% |
| Revenue growth rate | 24.6% |
| Future return on equity | 26.4% |
| Analyst coverage | Low |
| Last updated | 14 Aug 2024 |
Recent future growth updates
Recent updates
Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)
Sep 09
The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence
Aug 25Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40
May 28A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)
May 24Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge
May 08Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture
May 02Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital
Apr 13Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?
Mar 22Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce
Mar 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4,498 | 1,391 | N/A | 1,360 | 4 |
| 12/31/2025 | 3,651 | 1,054 | N/A | 1,044 | 4 |
| 12/31/2024 | 2,886 | 819 | N/A | 776 | 3 |
| 6/30/2024 | 2,406 | 711 | 926 | 1,229 | N/A |
| 3/31/2024 | 2,094 | 525 | 877 | 1,185 | N/A |
| 12/31/2023 | 1,922 | 436 | 669 | 917 | N/A |
| 9/30/2023 | 1,952 | 440 | 790 | 949 | N/A |
| 6/30/2023 | 1,949 | 419 | 609 | 872 | N/A |
| 3/31/2023 | 2,367 | 751 | 630 | 995 | N/A |
| 1/1/2023 | 2,491 | 890 | 408 | 884 | N/A |
| 9/30/2022 | 2,919 | 1,207 | 589 | 1,108 | N/A |
| 6/30/2022 | 3,041 | 1,325 | 670 | 1,206 | N/A |
| 3/31/2022 | 2,794 | 1,249 | 634 | 1,143 | N/A |
| 1/1/2022 | 2,675 | 1,197 | 712 | 1,249 | N/A |
| 9/30/2021 | 2,417 | 1,111 | 550 | 1,129 | N/A |
| 6/30/2021 | 2,269 | 1,055 | 575 | 1,110 | N/A |
| 3/31/2021 | 2,151 | 974 | 554 | 1,043 | N/A |
| 12/31/2020 | 1,951 | 875 | 600 | 957 | N/A |
| 9/30/2020 | 1,776 | 780 | 441 | 696 | N/A |
| 6/30/2020 | 1,643 | 706 | 431 | 669 | N/A |
| 3/31/2020 | 1,516 | 626 | 421 | 640 | N/A |
| 12/31/2019 | 1,432 | 571 | 363 | 583 | N/A |
| 9/30/2019 | 1,290 | 514 | 319 | 541 | N/A |
| 6/30/2019 | 1,219 | 498 | 236 | 465 | N/A |
| 3/31/2019 | 1,105 | 442 | 215 | 423 | N/A |
| 12/31/2018 | 1,017 | 402 | 211 | 384 | N/A |
| 9/30/2018 | 925 | 387 | 127 | 321 | N/A |
| 6/30/2018 | 846 | 345 | 161 | 317 | N/A |
| 3/31/2018 | 777 | 315 | N/A | 308 | N/A |
| 12/31/2017 | 718 | 284 | N/A | 304 | N/A |
| 9/30/2017 | 662 | 266 | N/A | 293 | N/A |
| 6/30/2017 | 612 | 251 | N/A | 283 | N/A |
| 3/31/2017 | 566 | 215 | N/A | 205 | N/A |
| 12/31/2016 | 544 | 202 | N/A | 179 | N/A |
| 9/30/2016 | 537 | 204 | N/A | 182 | N/A |
| 6/30/2016 | 547 | 209 | N/A | 192 | N/A |
| 3/31/2016 | 532 | 210 | N/A | 195 | N/A |
| 12/31/2015 | 509 | 200 | N/A | 205 | N/A |
| 12/31/2014 | 371 | 160 | N/A | 137 | N/A |
| 12/31/2013 | 304 | 127 | N/A | 133 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300529's forecast earnings growth (26.9% per year) is above the savings rate (2.9%).
Earnings vs Market: 300529's earnings (26.9% per year) are forecast to grow faster than the CN market (23% per year).
High Growth Earnings: 300529's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300529's revenue (24.6% per year) is forecast to grow faster than the CN market (13.2% per year).
High Growth Revenue: 300529's revenue (24.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300529's Return on Equity is forecast to be high in 3 years time (26.4%)